Literature DB >> 20160487

ZEB proteins link cell motility with cell cycle control and cell survival in cancer.

Gareth Browne1, A Emre Sayan, Eugene Tulchinsky.   

Abstract

Epithelial mesenchymal transitions (EMT), the generation of motile mesenchymal cells from epithelial sheets, are differentiation programs which take place at several critical steps of embryonic development and in metastatic cancer. Recent data have shown that the transcription factors which are master regulators of EMT also regulate cell cycle progression, apoptosis and senescence. In light of these new observations, the role of these factors in human cancer may be broader than previously anticipated. Here we review recent literature on non-EMT functions of EMT-controlling transcription factors. We will mainly focus on transcription factors belonging to the ZEB family, but some important results obtained by investigators studying other key EMT regulators, Snail and Twist are also discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160487     DOI: 10.4161/cc.9.5.10839

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  51 in total

Review 1.  The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Authors:  Simone Brabletz; Thomas Brabletz
Journal:  EMBO Rep       Date:  2010-08-13       Impact factor: 8.807

2.  Submucosal Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse Tracheal Epithelium.

Authors:  Thomas J Lynch; Preston J Anderson; Pavana G Rotti; Scott R Tyler; Adrianne K Crooke; Soon H Choi; Daniel T Montoro; Carolyn L Silverman; Weam Shahin; Rui Zhao; Chandler W Jensen-Cody; Andrea Adamcakova-Dodd; T Idil Apak Evans; Weiliang Xie; Yulong Zhang; Hongmei Mou; B Paul Herring; Peter S Thorne; Jayaraj Rajagopal; Charles Yeaman; Kalpaj R Parekh; John F Engelhardt
Journal:  Cell Stem Cell       Date:  2018-04-12       Impact factor: 24.633

3.  FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Authors:  Geng Zhang; Peijun He; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  Cancer Res       Date:  2013-06-25       Impact factor: 12.701

4.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

Authors:  Aaron P Putzke; Aviva P Ventura; Alexander M Bailey; Canan Akture; John Opoku-Ansah; Müge Celiktaş; Michael S Hwang; Douglas S Darling; Ilsa M Coleman; Peter S Nelson; Holly M Nguyen; Eva Corey; Muneesh Tewari; Colm Morrissey; Robert L Vessella; Beatrice S Knudsen
Journal:  Am J Pathol       Date:  2011-05-04       Impact factor: 4.307

5.  Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model.

Authors:  Gretchen M Argast; Joseph S Krueger; Stuart Thomson; Isabela Sujka-Kwok; Krista Carey; Stacia Silva; Matthew O'Connor; Peter Mercado; Iain J Mulford; G David Young; Regina Sennello; Robert Wild; Jonathan A Pachter; Julie L C Kan; John Haley; Maryland Rosenfeld-Franklin; David M Epstein
Journal:  Clin Exp Metastasis       Date:  2011-06-04       Impact factor: 5.150

6.  The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Authors:  Xiaochao Tan; Priyam Banerjee; Xin Liu; Jiang Yu; Don L Gibbons; Ping Wu; Kenneth L Scott; Lixia Diao; Xiaofeng Zheng; Jing Wang; Ali Jalali; Milind Suraokar; Junya Fujimoto; Carmen Behrens; Xiuping Liu; Chang-Gong Liu; Chad J Creighton; Ignacio I Wistuba; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

7.  MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells.

Authors:  Sharanjot Saini; Soichiro Yamamura; Shahana Majid; Varahram Shahryari; Hiroshi Hirata; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Res       Date:  2011-08-18       Impact factor: 12.701

Review 8.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

9.  MiR-141 targets ZEB2 to suppress HCC progression.

Authors:  Shi-Min Wu; Hong-Wu Ai; Ding-Yu Zhang; Xiao-Qun Han; Qin Pan; Feng-Ling Luo; Xiao-Lian Zhang
Journal:  Tumour Biol       Date:  2014-07-10

Review 10.  Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.

Authors:  Hae-Yun Jung; Laurent Fattet; Jing Yang
Journal:  Clin Cancer Res       Date:  2014-08-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.